ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Zingerone attenuates steatosis via downregulation of AQP9 in hepatocytes.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zingerone (ZO) found in Zingiber officinale, belonging to methoxyphenol family and its related derivatives, has been reported to ameliorate nonalcoholic fatty liver disease (NAFLD) by enhancing lipid metabolism and exerting hepatoprotective effects. However, the effect of ZO on hepatic AQP9 expression, along with the underlying mechanisms driving its hepatoprotective potential, remains largely unexplored. This study aims to investigate the modulatory effect of ZO on AQP9 expression in a steatosis cell model through experimental and in silico analyses, providing insights that could contribute to therapeutic interventions for NAFLD. Oleate-palmitate (OA-PA) and free fatty acids (FFA) induced hepatic steatosis was established in Hepa 1-6 cells as in vitro model of NAFLD. Cell cytotoxicity and lipid accumulation were evaluated by MTT assay and Oil-RedO staining, respectively. ZO pretreatment significantly attenuated intracellular lipid accumulation and altered the expression of aquaporins, resulting in downregulation of AQP9 and upregulation of AQP3 and AQP7, as demonstrated by qRT-PCR analysis. These findings suggest that ZO ameliorates OA-PA induced hepatic steatosis primarily by inhibiting lipid accumulation and selectively modulating aquaporin expression. Molecular docking analysis revealed that ZO forms a complex with AQP9 with the minimum binding energy of -6.2 kcal/mol. The molecular dynamics simulations showed that this complex stays stable across time with consistent RMSD and low RMSF values. In summary, pre-treatment with ZO has beneficial health effects by inhibiting lipid accumulation and selectively modulating aquaporin expression, highlighting its potential in preventing fatty liver disease.
Indexed as
Identifiers
41814034What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.